
Opinion|Videos|September 26, 2024
KEYNOTE-522 Update From ESMO 2024
Panelists discuss how updates from KEYNOTE-522 at ESMO 2024 revealed important data on overall survival and event-free survival outcomes.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
Lung Cancer News Roundup: June 2026
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5











































